Navigation Links
Cryo-Cell Renews Upromise Industry-Exclusive Agreement
Date:11/13/2008

Families Can Invest Simultaneously in Future Healthcare and Education

OLDSMAR, Fla., Nov. 13 /PRNewswire-FirstCall/ -- Cryo-Cell International Inc., one of the world's largest and most established private cord blood banks and industry leader in stem cell innovation, recently renewed their agreement as an exclusive retailer with Upromise(R) the largest private source of college funding contributions in America. Since 2004, Cryo-Cell has been the only cord blood bank in the United States to offer enrollment in the Upromise program and has contributed nearly $250,000 to Upromise member accounts. Under the renewed agreement, parents who use their Upromise-registered credit card to pay for their cord blood banking enrollment and/or storage fees will be awarded with 2 percent college savings.

"Cryo-Cell is very proud to be the first and only retailer in the cord blood banking industry to offer Upromise," said Michelle Kay, Director of Marketing. "During challenging economic times, it is particularly meaningful that Cryo-Cell families have the significant opportunity to invest simultaneously in their family's future healthcare and educational needs."

Cord blood stem cells have already been used to treat more than 75 diseases, including numerous types of malignancies, anemia, inherited metabolic disorders and deficiencies of the immune system. To date, Cryo-Cell has contributed nearly a quarter of a million dollars to the Upromise accounts of their clients. Cryo-Cell plans to co-market its services to the large and fast-growing installed base of over 9 million Upromise members by providing timely information and updates on the potential of regenerative stem cell therapies to treat a vast number of debilitating diseases and disorders.

"Cryo-Cell is committed to helping Americans achieve their educational goals," said Kelly Christiano, Executive Vice President of Partner Management for Upromise. "When parents are considering cord blood bankin
'/>"/>

SOURCE Cryo-Cell International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
3. Cryo-Cell International, Inc. Reports First Quarter 2008 Results
4. Cryo-Cell International, Inc. Reports Second Quarter 2008 Results
5. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
6. Cryo-Cell International, Inc. Reports Third Quarter 2008 Results
7. Biomaxx Systems Inc. Renews Membership With Bioenergy Australia
8. Osteotech Renews Tissue Recovery Agreement with the Euro Atlantic Transplant Alliance
9. China Biologics Production Facility Renews GMP Certification
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2From fruit fly wings to heart failure -- why Not(ch)? 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Sunrise Reports Financial Results for Second Quarter 2009 53821 1Sunrise Reports Financial Results for Second Quarter 2009 53821 2Sunrise Reports Financial Results for Second Quarter 2009 53821 3Sunrise Reports Financial Results for Second Quarter 2009 53821 4Sunrise Reports Financial Results for Second Quarter 2009 53821 5Sunrise Reports Financial Results for Second Quarter 2009 53821 6Sunrise Reports Financial Results for Second Quarter 2009 53821 7Sunrise Reports Financial Results for Second Quarter 2009 53821 8Sunrise Reports Financial Results for Second Quarter 2009 53821 9Sunrise Reports Financial Results for Second Quarter 2009 53821 10Sunrise Reports Financial Results for Second Quarter 2009 53821 11Sunrise Reports Financial Results for Second Quarter 2009 53821 12Sunrise Reports Financial Results for Second Quarter 2009 53821 13Sunrise Reports Financial Results for Second Quarter 2009 53821 14Sunrise Reports Financial Results for Second Quarter 2009 53821 15Sunrise Reports Financial Results for Second Quarter 2009 53821 16Sunrise Reports Financial Results for Second Quarter 2009 53821 17Sunrise Reports Financial Results for Second Quarter 2009 53821 18Sunrise Reports Financial Results for Second Quarter 2009 53821 19Sunrise Reports Financial Results for Second Quarter 2009 53821 20Micromet Inc Reports Second Quarter 2009 Financial Results 53819 1Micromet Inc Reports Second Quarter 2009 Financial Results 53819 2Micromet Inc Reports Second Quarter 2009 Financial Results 53819 3Micromet Inc Reports Second Quarter 2009 Financial Results 53819 4Micromet Inc Reports Second Quarter 2009 Financial Results 53819 5Micromet Inc Reports Second Quarter 2009 Financial Results 53819 6Micromet Inc Reports Second Quarter 2009 Financial Results 53819 7Micromet Inc Reports Second Quarter 2009 Financial Results 53819 8Micromet Inc Reports Second Quarter 2009 Financial Results 53819 9Micromet Inc Reports Second Quarter 2009 Financial Results 53819 10Micromet Inc Reports Second Quarter 2009 Financial Results 53819 11Ben Shappley Joins Amedicas Leadership Team 53817 1Ben Shappley Joins Amedicas Leadership Team 53817 2